Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: Automatic provisioning of an access point base station or femtocell. The method may include the femtocell transmitting first information (e.g., location information, signal measurement information, capability information, etc.) to a service provider (e.g., over an IP network). The femtocell may receive second information from the service provider, where the second information includes one or more operational parameters. The operational parameters may include hand-off parameters, admission policy parameters, PN or scrambling codes, power parameters, and/or other parameters. The femtocell may operate according to the received parameters to provide access for a plurality of access terminals in a local area.

Abstract: Automatic provisioning of an access point base station or femtocell. The method may include the femtocell transmitting first information (e.g., location information, signal measurement information, capability information, etc.) to a service provider (e.g., over an IP network). The femtocell may receive second information from the service provider, where the second information includes one or more operational parameters. The operational parameters may include hand-off parameters, admission policy information, PN or scrambling codes, power parameters, and/or other parameters. The femtocell may operate according to the received parameters to provide access for a plurality of access terminals in a local area.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.

Abstract: Time synchronization of an access point base station. The method may include receiving an assignment message from a service provider comprising a plurality of parameters. The plurality of parameters may include an access point base station frequency assignment, a network identifier, an access point base station identifier, a neighbor list, a PN offset, and/or a scrambling code. The access point base station may then synchronize with the macro base station. Synchronizing may include searching for a strongest macro base station in the neighbor list, synchronizing a long code of the access point base station to the macro base station, estimating a propagation delay between the macro base station and the access point base station, and initializing a state of the access point base station PN code using the propagation delay to provide system time synchronization.

Abstract: Described herein are methods of treating a disorder affecting the mesangial cells in a subject by administering an engineered nanoparticle (ENP) capable of delivering a therapeutic agent to the subject. Also provided are diagnostic methods for administering to a subject an ENP, analyzing a mesangial cell of the subject and determining whether the engineered nanoparticle is present in a mesangial cell of the subject.

Abstract: Described herein are methods of treating a disorder affecting the mesangial cells in a subject by administering an engineered nanoparticle (ENP) capable of delivering a therapeutic agent to the subject. Also provided are diagnostic methods for administering to a subject an ENP, analyzing a mesangial cell of the subject and determining whether the engineered nanoparticle is present in a mesangial cell of the subject.

Abstract: Micro-cavity resonant sensors have outer surfaces that are functionalized using click chemistry, e.g., involving a cycloaddition reaction of an alkyne functional group and an azide functional group. A first polymer linking element binds to an outer surface of the micro-cavity and has an azide functional group, which bonds to an alkyne functional group of a second polymer linking element as a result of a cycloaddition reaction. A functionalization element such as an antibody, antigen or protein for sensing a target molecule is bound to the second linking element.

Abstract: A bowling lane maintenance machine has a cleaning assembly in which liquid cleaner is deposited on the lane surface at the front of the machine as the machine moves down the lane. Immediately behind the point of application of the cleaning solution, a wiping web assembly spreads the solution across the entire surface of the lane and presses the solution down into the conditioner for subsequent pickup by a suction pickup head behind the wiper web assembly. The web is looped under a backup roll having an exposed fibrous pile face that engages the inside surface of the web while the outside surface engages the lane. The fibrous pile encourages the web to remain in intimate contact with the lane surface at all times while accommodating surface irregularities such as depressions and other variations in lane contour.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: A sustained-release biodegradable polymeric drug-eluting fiber is disclosed. In some embodiments, the therapeutic drug is complexed with cyclodextrin. In certain embodiments, the polymeric component of the fiber comprises cyclodextrin. The fiber may be fabricated to provide a thread and/or suture. The fiber may be used for treatment of ocular diseases or disorders.

Abstract: The present invention relates to inhibitors of endothelial PAS domain protein 1 (EPAS1), and methods and compositions related to the EPAS1 inhibitors. In certain embodiments, the EPAS1 inhibitors include nucleic acids, such as for example siRNAs.

Abstract: A prefabricated outbuilding may include a first vertically oriented upright, a support beam supported by the vertically oriented upright, a groove supporting structure extending over the first vertically oriented upright, a second upright to support the roof support structure, an accessory including an upper end and a lower end to support the prefabricated outbuilding. The upper end may receive the lower end of the first vertically oriented upright, and the lower end may be adapted to drive into a support surface. The support surface may be earth, and the support surface may be concrete. The lower end may include an aperture to receive rebar, and the upper and may include an aperture to receive a fastener. The prefabricated outbuilding may include a roof support beam to support a roof, and the prefabricated outbuilding may include a deck. The prefabricated outbuilding may be transportable, and the pre-fabricated outbuilding may include at least two enclosures and may include four enclosures or more.

Abstract: A forward and backward compatible streaming protocol requires subsequent versions of the protocol to be purely additive relative to earlier versions. When a data segment is transmitted as a data stream, a first stream of data that is in accordance with a first version of the protocol is transmitted, with additional streams of data that are in accordance with subsequent versions of the protocol appended in sequence to the first stream of data. When a read module implements an earlier version of the protocol than a write module, the data segment is truncated to include only the data supported by the version implemented by the read module. On the other hand, when the read module implements a later version of the protocol than the write module, receipt of the data segment is terminated after the data supported by the version implemented by the write module is received.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.